

November 23, 2015



Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2015

27th Annual Piper Jaffray Healthcare Conference Presentation With Live Webcast on December 1st at 8:30 a.m. ET; Oppenheimer 26th Annual Healthcare Conference Presentation With Live Webcast on December 8th at 10:20 a.m. ET

NORWOOD, MA -- (Marketwired) -- 11/23/15 -- [Corbus Pharmaceuticals Holdings, Inc.](#) (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at two upcoming investor conferences in December.

Event: 27th Annual Piper Jaffray Healthcare Conference

Date: Tuesday, December 1, 2015

Time: 8:30 a.m. Eastern Time

Location: New York Palace Hotel, New York City

Event: Oppenheimer 26th Annual Healthcare Conference

Date: Tuesday, December 8, 2015

Time: 10:20 a.m. Eastern Time

Location: Westin Grand Central Hotel, New York City

Dr. Cohen will provide a corporate overview and discuss the progress of the Company's three clinical trial programs for [Resunab™](#). Resunab is a novel synthetic oral drug intended to resolve chronic inflammation and halt fibrosis. The drug is currently being evaluated in three separate Phase 2 clinical studies in [cystic fibrosis](#) ("CF"), diffuse cutaneous [systemic sclerosis](#), and skin-predominant [dermatomyositis](#). Corbus expects to report top-line safety and efficacy results from these Phase 2 studies starting at the end of 2016.

Live webcasts of both presentations will be available by accessing the [R Calendar](#) the [Investors](#) section of the Corbus website (www.CorbusPharma.com). The webcast replays will be available approximately two hours after each presentation ends and will be accessible for one month.

About Resunab™

Resunab™ is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Pre-clinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Resunab triggers the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab™, is a novel synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation, bacterial infections, and fibrotic processes. Resunab is currently in Phase 2 studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis and skin-predominant dermatomyositis.

For more information, please visit www.CorbusPharma.com and connect with the Company on [Twitter](#), [LinkedIn](#), [Google+](#) and [Facebook](#).

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact

Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: [Email Contact](#)

Media Contact

David Schull or Marissa Goberdhan
Russo Partners, LLC
Phone: +1 (858) 717-2310
Email: [Email Contact](#)
Email: [Email Contact](#)

Source: Corbus Pharmaceuticals Holdings Inc